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Edited by Beat ImhofAbstract Integrin–ﬁlamin binding plays an important role in
adhesion-mediated control of the actin cytoskeleton. Here, using
the interaction between recombinant fragments from the C-
terminus of ﬁlamin A and the cytoplasmic tail of integrin b7 as a
model, we report a negative regulatory role for ﬁlamin alterna-
tive splicing. Splice variant forms of ﬁlamin A lacking a 41-
amino acid segment interacted more strongly than full-length
fragments. In addition, we provide evidence that phosphorylation
of the splice variant region is unlikely to represent the
mechanism by which binding is reduced.
 2004 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Cell migration1. Introduction
Integrins are heterodimeric receptors involved in cell–cell
and cell–extracellular matrix interactions [1]. Integrins spa-
tially compartmentalize signalling molecules [2] and link the
extracellular matrix to the intracellular actin cytoskeleton,
thereby regulating cell polarity and motility [3]. Many diﬀerent
intracellular proteins have been shown to interact with integrin
cytoplasmic domains [4–6], including signalling adaptors and
cytoskeletal proteins.
A key integrin-binding protein is ﬁlamin [7]. Filamin is a
280-kDa rod-shaped protein, composed of an N-terminal ac-
tin-binding domain (ABD), 24 homologous 100 amino acid
repeating modules, and two ﬂexible hinge regions (between
repeats 15–16 and 23–24) (Fig. 1A). Filamin forms parallel
homodimers via the C-terminal 24th repeats, with the dimer
adopting a V-like shape, as determined by electron microscopy
[8]. The repeats are primarily composed of b-strands, although
structural information for higher-order ﬁlamin proteins is
lacking. Filamin crosslinks actin, forming either loose micro-
ﬁlament networks, or tight actin bundles, depending on the
ratio of actin:ﬁlamin present [9,10]. In addition, ﬁlamin inter-
acts with a large number of cytosolic proteins and may play
important roles in the recruitment of such signalling factors to* Corresponding author. Fax: +44-161-275-1505.
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cells, termed ﬁlamin-A, -B and -C. Filamin-A and -B are
ubiquitously expressed, whereas expression of ﬁlamin-C is re-
stricted to skeletal and cardiac muscle [7].
Filamin has been shown to interact with the b cytoplasmic
domain of several integrins, including b1, b2, b3 and b7 [11–14].
Binding of ﬁlamin to b integrin tails has been shown to be
important in the regulation of cell migration, as the b7 integrin
tail, which binds strongly to ﬁlamin and plays a key role in a
variety of leukocyte traﬃcking events, supported low levels of
cell migration, whereas b1 tails that bind weakly to ﬁlamin (b1A
and b1D) supported higher levels of cell migration [11].
Repeats 19–24 of ﬁlamin mediate the interaction with the
integrin b1 tail [12,15]. A splice variant within this region has
been discovered in which 41-amino acids are removed from a
site between repeats 19 and 20: removal of this segment in-
creased ﬁlamin aﬃnity for the b1 tail in vitro and as a conse-
quence stimulated myoblast diﬀerentiation [15].
In view of the potential link between ﬁlamin binding and
regulation of integrin-mediated migration, we have investi-
gated the interaction of ﬁlamin splice variants with the integrin
b7 tail, using the interaction between a recombinant fragment
from the C-terminus of ﬁlamin and the cytoplasmic tail of
integrin b7 as a model system. We show that ﬁlamin splice
variants interact more strongly with the b7 tail than wild-type
fragments, indicating that the 41 amino acid splice region acts
as a negative regulator of integrin binding. We also show that
phosphorylation of the ﬁlamin splice region does not likely
represent the mechanism by which integrin binding is reduced,
suggesting that the splicing has a structural eﬀect on the inte-
grin-binding site within the ﬁlamin.2. Materials and methods
2.1. Production of integrin tail model peptides
Full-length cDNA encoding integrin a4 and b7 were kindly donated
by Dr. Christelle Perros-Huguet (Pﬁzer Ltd., Sandwich, Kent, UK).
The integrin tails were expressed as 6· His-tagged proteins, with a
coiled-coil region inserted onto the N-terminus of the protein
(sequence GGCGGAQLKKKLQALKKKNAQLKWKLQALKKK-
LAQ, from [16]). Due to the insertion of a Cys residue at the N-ter-
minus of the coiled-coil, the integrin tails form homodimeric structures
(data not shown).
To produce the coiled-coil, overlapping PCR was performed, in-
serting a 50 BamHI and 30 EcoRI restriction site. After digestion withblished by Elsevier B.V. All rights reserved.
Fig. 1. Predicted structure of ﬁlamin. (A) Schematic structure of ﬁlamin. Although structural information is lacking for mammalian ﬁlamins,
predictions have been made based on amino acid sequence. There is predicted to be an N-terminal ABD (red), followed by 24 repeating units of 96
amino acids (blue), predicted to form b-sheet structure. Two hinge regions (gold) are inserted between repeats 15–16 and 23–24. Parallel dimers are
formed by non-covalent interactions mediated via repeat 24. (B) Schematic representation of C-terminal fragments of ﬁlamin used. Both constructs
were tagged with HA at their N-termini (green). The splice variant of ﬁlamin A has 41-amino acids removed from between repeating units 19 and 20.
Filamin repeats are shown in blue, with the hinge region shown in orange.
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pHis, a modiﬁed version of pET-15 (Novagen, Madison, WI, USA),
encoding an N-terminal 6· His tag [17].
To clone the cytoplasmic domain regions of integrin a4 and b7, the
tail regions (K968-D999 for a4, R728-L779 for b7) were ampliﬁed by
PCR, inserting a 50 MfeI and 30 EcoRI restriction site. The product was
digested with MfeI–EcoRI and ligated into EcoRI-digested pHis con-
taining the coiled-coil construct. Correct ligation destroys the 50 MfeI
restriction site, resulting in a 50 BamHI–30 EcoRI fragment encoding
the coiled-coil upstream from the integrin cytoplasmic domain. Cor-
rect insertion and sequence of the constructs was veriﬁed by DNA
sequencing.
To express the integrin cytoplasmic tail proteins, JM109 (DE3)
bacterial cells were transformed with integrin tail DNA, grown with
shaking at 37 C, and protein expression induced by addition of 1 mM
IPTG. After 4 h, cells were harvested by centrifugation and resus-
pended in 40 ml/l binding buﬀer (0.5 M NaCl and 20 mM Tris–HCl,
pH 7.9). Bacteria were lysed on ice by 6· 30 s sonication at 20% am-
plitude using a stepped microtip and a Vibra Cell sonicator (Sonics and
Materials Inc., Newtown, CT, USA). The majority of integrin tail
protein expressed was found to be insoluble (data not shown), hence
lysates were centrifuged at 40 000· g for 20 min to isolate inclusion
bodies. Pellets were resuspended in binding buﬀer plus 5 mM imidazole
and 6 M urea, and incubated on ice for 30 min. Cellular debris was
removed by centrifugation at 40 000· g for 20 min, and integrin tail
puriﬁed from dissolved inclusion body lysate by nickel aﬃnity chro-
matography, using Nickel–NTATM agarose (Qiagen Ltd., Crawley,
UK). Integrin peptides were then further puriﬁed by RP-HPLC, using
a C18 column (Phenomenex, Macclesﬁeld, UK) and an AKTA puriﬁer
system (Amersham Pharmacia, Buckinghamshire, UK). Peak protein
fractions were lyophilized by rotary evaporation under vacuum,resuspended in 20 mM PIPES, pH 6.8, 50 mMNaCl, and stored at )80
C until use.
2.2. Aﬃnity chromatography pull-down assay
COS-1 cells were transfected with ﬁlamin constructs encoding the C-
terminal repeats 19–24, tagged at their N-terminus with an HA tag [15]
(Fig. 1) using Lipofectamine 2000TM (Invitrogen, Paisley, UK) ac-
cording to the manufacturer’s instructions. Cells were lysed 48 h post-
transfection in lysis buﬀer [buﬀer A (20 mM PIPES, pH 6.8 and 50 mM
NaCl) plus 150 mM sucrose, 3 mM MgCl2, 50 mM NaF, 40 mM Na
pyrophosphate, 1% (w/v) Triton X-100, 1 mM NaVO3, 1 mM PMSF,
20 lg/ml aprotinin and 5 lg/ml leupeptin] to a cell number of 1 107/
ml. Integrin cytoplasmic domains were loaded onto nickel–agarose
beads by addition of 20 lg of tail protein to 800 ll buﬀer A plus 200 ll
of 100 mM NaOAc, pH 3.5, containing 20 ll of Nickel–NTATM
agarose, for each experiment [13]. The mixture was rotated for 2 h at 4
C and the beads were washed twice with buﬀer A before use in
experiments.
50 ll of cell lysate was added to 450 ll of buﬀer A (plus 1 mM
PMSF, 20 lg/ml aprotinin and 5 lg/ml leupeptin), together with the
integrin tail-loaded nickel–agarose beads, and rotated overnight at 4
C. Beads were washed ﬁve times with buﬀer A and boiled in 40 ll
reducing Laemmli SDS sample buﬀer to release any bound proteins. 20
ll of the sample was resolved by SDS–PAGE, proteins transferred to
nitrocellulose membrane, and HA-ﬁlamin detected by Western blot
using an antibody directed against the HA tag (sc-805, Santa Cruz
Biotechnology Inc., Santa Cruz, CA). The remaining 20 ll of the
sample was resolved by reducing SDS–PAGE and Coomassie blue
stained, to check integrin tail load in each experiment. 12.5 ll of cell
lysate was loaded and subjected to Western blot using the anti-HA
antibody to ensure equal ﬁlamin protein load in each experiment.
Fig. 2. Binding of mammalian expressed HA-Fln A19–24(41) and Fln
A19–24(0) to integrin cytoplasmic domains. (A) Aﬃnity chromatogra-
phy assay, assessing binding of HA-ﬁlamin transfected COS-1 lysates
to integrin tails. (B) Densitometry values for binding of HA-ﬁlamin
molecules to the b7 tail (average of three experiments, error bars are
S.E.M.; *, signiﬁcant P < 0:05 using paired Student’s t-test).
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a GS-700 imaging densitometer and Molecular Analyst software
(BioRad, Hertfordshire, UK). Results from at least three experiments
were used to obtain average values. Statistical analyses of the results
were performed using a paired Student’s t-test.
2.3. GST-ﬁlamin expression and protein kinase A assay
Repeats 19–24 of ﬁlamin A(41) or A(0) were ampliﬁed by PCR and
ligated into the GST-encoding vector pGEX 4-T-1 (Amersham Bio-
sciences, Buckinghamshire, UK) using a 50 EcoRI and 30 XhoI re-
striction site. Proteins were expressed by transformation into JM109
bacteria, incubation at 37 C with shaking, and induction with 1 mM
IPTG. After induction, cells were incubated at 30 C for 4 h before
harvesting and resuspended in 40 ml/l binding buﬀer. Cells were lysed
by sonication as above and GST-ﬁlamin protein puriﬁed using gluta-
thione agarose aﬃnity chromatography. Doses of GST-ﬁlamin protein
were added to kinase buﬀer (25 mM HEPES, pH 7.4, 25 mM b-glyc-
erophosphate and 3 mM MgCl2) containing 1 mM ATP, 1 mM DTT,
5 lCi [c32P]ATP (Perkin–Elmer Life and Analytical Sciences, Buck-
inghamshire, UK), and 1 U protein kinase A (PKA, Sigma, Poole,
Dorset, UK). Sterile dH2O was added up to 20 ll and samples incu-
bated at 30 C for 90 min. Samples were then resolved by reducing
SDS–PAGE and gels Coomassie blue, stained to reveal protein bands.
32P-labelled proteins were visualized by autoradiography via exposure
to photographic ﬁlm and processing by an automatic ﬁlm processor
(Kodak, Rochester, NY).
2.4. Binding to GST Fusion Proteins
Pull-down assays have been performed as described previously [15].
Brieﬂy, bacterially expressed glutathione S-transferase fused to either
b1A, b1D, and b7 cytoplasmic domains were puriﬁed. Subsequently, 50
lg puriﬁed fusion proteins were bound to 15 ll glutathione–Sepharose-
4B beads and were incubated overnight at 4 C with total cell lysates of
DEAE-dextran transfected COS-7 cells expressing HA-tagged trun-
cated ﬁlamin proteins. After washing with lysis buﬀer (10 mM can, pH
6.8, 50 mM NaCl, 150 mM sucrose, 0.5% Triton X-100, and 1 mM
EDTA, and protease inhibitors), beads were centrifuged through a
sucrose cushion (10 mM can, pH 6.8, 50 mM NaCl, 800 mM sucrose
and 1 mM MgCl2) and proteins were resolved by SDS–PAGE. HA-
tagged ﬁlamin fusion proteins were visualized and quantiﬁed by im-
munoblotting using anti-HA antibody (12CA5) and enhanced
chemoﬂuorescence (Amersham). GST-fusion protein loading of the
beads was checked by Coomassie brilliant blue staining.3. Results and discussion
3.1. Binding of ﬁlamin fragments to the integrin b7 tail
It has been shown previously that sites in the C-terminus of
ﬁlamin mediate binding to the integrin b1 tail [12,15]. To de-
termine whether similar sites are involved in the interaction with
the integrin b7 tail, a C-terminal fragment of ﬁlamin A, en-
coding repeating units 19–24 of the protein and the 41-amino
acid splice segment [Fln A19–24(41)], was expressed in COS-1
cells (Fig. 1B(i)). Following cell lysis, the binding of the re-
combinant ﬁlamin fragment to a proteinmimic of the b7 tail was
assessed using an aﬃnity chromatography pull-down assay.
Fln A19–24(41) was found to bind to the b7 tail, but not to a
protein mimic of the integrin a4 tail (Fig. 2A), suggesting that,
as for the b1 integrin tail, sites in the C-terminus of ﬁlamin are
involved in binding to the integrin b7 tail.
It has recently been reported that a splice variant fragment of
ﬁlamin, in which the 41-amino acid segment between repeating
units 19 and 20 was removed, interacted more strongly with the
b1 tail than did a fragment containing the spliced region [15].
To determine the role of alternative splicing in regulating ﬁl-
amin–b7 tail interactions, COS-1 cells were transfected with an
HA-tagged construct lacking the 41-amino acid segment [Fln
A19–24(0); Fig. 1B(ii)], and binding to the b7 tail assessed using
the aﬃnity chromatography assay employed above.Binding of splice variant Fln A19–24(0) to the integrin b7 tail
was apparent, but not to a mimic of the a4 integrin tail
(Fig. 2A), and it appeared to be stronger than that seen with
Fln A19–24(41) (Fig. 1B). Indeed, quantitation of binding using
densitometry showed that binding of the splice variant Fln
A19–24(0) was threefold higher than that seen for Fln A19–24(41)
(values for Fln A19–24(41)¼ 7.38, Fln A19–24(41)¼ 21.63,
Fig. 2B). Thus, as was observed for the b1 tail [15], binding of
Fln A19–24(0) was stronger than that seen for Fln A19–24(41).
This suggests that there are elements present in the 41-amino
acid splice variant region of ﬁlamin that act to reduce binding
of ﬁlamin to integrin b tails.
As ﬁlamin has been reported to bind more strongly to b7 than
to b1, the binding of Fln A19–24(41) and Fln A19–24(0) to the b1A,
b1D, and b7 integrin tails was compared in parallel. As shown in
Fig. 3, in pull-down assays, b7 bound higher amounts of both
Fln A19–24(41) and Fln A19–24(0) than either of the b1 con-
structs. For all integrin tails, however, binding of Fln A19–24(0)
was higher than that of Fln A19–24(41) (Fig. 3). Thus, although
diﬀerent integrin cytoplasmic domains have diﬀerent aﬃnities
for ﬁlamin, the eﬀects of alternative splicing on receptor bind-
ing are qualitatively the same for diﬀerent integrins. This sug-
gests that the same mechanisms are employed to regulate
ﬁlamin–integrin associations within diﬀerent cell types.
3.2. Role of phosphorylation of the splice region in regulating
the ﬁlamin–integrin tail interaction
There are several possible explanations for the results
obtained above, including a steric interference of the splice
Fig. 3. Comparison of binding of mammalian expressed HA-Fln
A19–24(41) and Fln A19–24(0) to b1 and b7 integrin cytoplasmic do-
mains. (A) COS cell lysates immunoblotted with anti-HA antibody to
show levels of expression of the Fln A19–24(41) and Fln A19–24(0)
variants. (B) Pull-down assay using GST-tagged b1A, b1D, and b7 in-
tegrin cytoplasmic domains. Top: immunoblot detection of bound
ﬁlamin by anti-HA blotting. Bottom: Coomassie blue staining showing
the amount of each integrin fusion protein used in each assay.
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segment on ﬁlamin conformation, and a role for the splice
segment as a negative regulatory element, possibly due to post-
translational modiﬁcation. The amino acid sequence of FlnB
A
Fig. 4. Prediction of phosphorylated residues in the variable splice region o
potential kinase phosphorylation sites (http://www.cbs.dtu.dk/databases/Pho
these sites were phosphorylated (http://www.cbs.dtu.dk/services/NetPhos/). A
calmodulin-dependent protein kinase II; CKII, casein kinase II; p70S6K, S6A19–24(41) is shown in Fig. 4 and the 41-amino acid splice
variant region is highlighted. The spliced region contains a
number of serine and threonine residues that could be poten-
tially phosphorylated in mammalian cells. It has been widely
documented that ﬁlamin is a highly phosphorylated protein [7],
and there are also examples where phosphorylation regulates
the interaction of a protein ligand with an integrin cytoplasmic
domain (for example, paxillin with a4 [18], Shc with b3 [19]).
Hence, it is plausible that phosphorylation of the spliced re-
gion of ﬁlamin may regulate binding to the b7 tail.
To investigate whether phosphorylation of the splice variant
region was involved in the regulation of binding to the b7 tail,
potential phosphorylation sites in the splice variant region
were identiﬁed using the phosphorylation prediction progra-
mmes PhosphoBase v.2.0 (http://www.cbs.dtu.dk/databases/
PhosphoBase/), and NetPhos v.2.0 (http://www.cbs.dtu.dk/
services/NetPhos/) (Fig. 4). PhosphoBase is a database that
predicts potential phosphorylation sites based on consensus
sequences in other proteins [20], whereas NetPhos is a pro-
gramme based on neural networks that predicts the probability
that a particular residue will be phosphorylated [21]. Fig. 4B
portrays residues that have a high probability of phosphory-
lation and/or are contained in a consensus sequence for a
common kinase.
PKA has been implicated in the regulation of integrin
function by phosphorylating proteins in close proximity to the
integrin cytoplasmic domains [18,22], and it is therefore a good
candidate kinase for phosphorylating ﬁlamin. Indeed, there is
evidence that PKA is capable of phosphorylating C-terminal
regions of ﬁlamin, as shown by in vitro phosphorylation of 
f ﬁlamin A repeats 19–24. (A) PhosphoBase v.2.0 was used to predict
sphoBase/) and NetPhos v.2.0 was used to predict the probability that
bbreviations: PKA, protein kinase A; PKC, protein kinase C; CaMII,
protein kinase).
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idue, Ser-2152, is predicted to be phosphorylated by PKA in
the splice variant region with a high probability (P ¼ 0:968,
Fig. 4B). Interestingly, recent work has shown that phos-
phorylation of ﬁlamin on S2152 by the kinase p21 activated
kinase-1 is important in regulating cell migration [24], a cel-
lular process also shown to be regulated by the ﬁlamin–b7
interaction [11], and that S2152 is phosphorylated by PKA
[23]. Hence, as S2152 can be phosphorylated in vivo, and this
phosphorylation is functionally important, this residue was
chosen for further study.
To test whether phosphorylation of Ser-2152 was important
in regulating the ﬁlamin A–b7 tail interaction, Ser-2152 was
mutated to alanine (S2152A) and aspartate (S2152D). Muta-
tion to alanine renders the residues non-phosphorylatable,
whereas mutation to aspartate was intended to mimic a con-
stitutively expressed phosphate group. As a control mutation,
Ser-2131 [a potential protein kinase C (PKC) phosphorylation
site (see Fig. 4)] was also mutated to Ala and Asp.
If phosphorylation of Ser-2152 were important in negatively
regulating ﬁlamin binding to the integrin b7 tail, one would
expect that mutation to alanine (resulting in removal of the
inhibitory phosphorylation site) would cause an increase in b7
tail binding to Fln A19–24(41) protein. Mutation to aspartate
would result in constant occupation of the inhibitory phos-
phorylation site, hence a decrease in binding to the b7 tail
would be expected, compared to the wild-type Fln A19–24(41)
protein.
3.3. Phosphorylation of ﬁlamin A repeats 19–24 by PKA
To test whether there is indeed a PKA phosphorylation site
in the spliced region of the Fln A19–24(41) construct, and to test
whether this site is S2152, an in vitro PKA assay was per-
formed, using bacterially expressed GST-Fln A19–24(41) (WT,
control S2131A and S2152A) and GST-Fln A19–24(0) as
substrates.
For wild-type and potential PKC site mutant (S2131A)
GST-Fln A19–24(41), a strong, dose-dependent incorporation
of [c32P] ATP was apparent, whereas only a weak incorpora-
tion was seen for the spliced GST-Fln A19–24(0) (Fig. 5). Mu-
tation of S2152 to Ala in Fln A19–24(41) reduced the signal toFig. 5. PKA assay using wild-type and mutant GST-ﬁlamin as substrate. PK
buﬀer plus 5 lCi [c32P]ATP. Protein was resolved by reducing SDS–PAGE an
autoradiography.levels seen for the splice variant GST-Fln A19–24(0) (Fig. 5).
This ﬁnding indicates that the major PKA phosphorylation
site in repeats 19–24 of ﬁlamin A is S2152, situated within the
splice variant region.
3.4. Eﬀect of potential phosphorylation site mutants on binding
to the b7 tail
To test whether mutation of the potential PKA (and PKC)
phosphorylation sites in the splice variant region of ﬁlamin A
aﬀects binding to the b7 tail, aﬃnity chromatography assays,
using Fln transfected COS-1 cell lysates, were performed. As
shown earlier, none of the mammalian HA-Fln constructs
bound to the a4 tail (Fig. 6). Wild-type Fln A19–24(41) bound
with weaker aﬃnity to the b7 tail than the splice variant form
Fln A19–24(0) (Fig. 6). All mutations of S2131 and S2152 had
negligible eﬀects on the binding of Fln to the b7 tail versus
wild-type (Fig. 6). These data indicate that phosphorylation of
S2131 or S2152 does not play a role in regulating the inter-
action of ﬁlamin with the b7 integrin tail.
Thus, in summary, the major ﬁnding in this report is that
inclusion of the 41-amino acid splice segment in ﬁlamin-A
reduces binding to the integrin b7 cytoplasmic tail. There are
several additional explanations for the suppression of integrin
binding. First, the splice region may mask a binding site for the
integrin tail or alter the conformation of the integrin binding
site so as to lower the aﬃnity of the interaction, as previously
suggested by van der Flier and Sonnerberg [7]. It is likely that a
deﬁnitive resolution of this possibility will require structure
determination of the C-terminal region of ﬁlamin. Second,
phosphorylation may be important in regulating the ﬁlamin–
b7 tail interaction, but our studies may not have identiﬁed the
correct regulatory residues in the molecule. For example, res-
idues outside the spliced region could potentially be phos-
phorylated and exert a long distance eﬀect. In the Fln
A19–24(41) construct, there are 29 potential phosphorylation
sites outside the splice variant region. There is a precedent for
long distance conformational regulation of binding to integrin
tails, as activation signals unmask the binding site for the b3
tail in the head region of talin [25]. Third, other factors may
bind to the spliced region of ﬁlamin and alter its binding
properties. A plethora of intracellular proteins can bind toA was added to doses of wild-type and mutant GST-ﬁlamin in kinase
d stained with Coomassie blue. 32P-labelled proteins were visualized by
Fig. 6. Binding of wild-type and mutant GST-ﬁlamin to integrin cytoplasmic domains. (A) HA-ﬁlamin transfected COS-1cell lysates were incubated
with nickel charged beads loaded with a4 or b7 tail. Bound protein was eluted from the beads, resolved by reducing SDS–PAGE, and Western blotted
for anti-HA to detect bound ﬁlamin protein. (B) Lysates (1/4 of total input in A) were resolved by SDS–PAGE, transferred to nitrocellulose
membrane, and Western blotted with an anti-HA antibody in order to check that expression of each of the HA-ﬁlamins was approximately equal.
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It is possible that a binding protein expressed in the COS-1
system binds to Fln A19–24(41) directly to the splice variant
region, causing a reduction in binding to the b7 tail compared
to the Fln A19–24(0) that lacks the splice variant. Alternatively,
a protein may bind to a site distal to the splice region, but
induce conformational changes (involving this region) that
result in reduced b7 tail binding. Further investigation of the
mechanisms underlying the role of alternative splicing in reg-
ulating integrin–ﬁlamin binding are likely to provide useful
insights into the cellular signalling mechanisms employed to
control migration.
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